TRH
- Category
- Brain & Cognition
- Administration routes
- InjectableNasal
- Regulatory status
- Not FDA-approved
What it is
A tripeptide that triggers pituitary release of TSH and prolactin, used off-label for effects on mood, alertness, and seizure threshold. Anticonvulsant and arousal-reversing effects have modest evidence, but neuroprotection claims rest almost entirely on animal studies. The main risk is thyroid axis disruption and blood pressure shifts, worsened by a short half-life. It is not an FDA-approved drug and is sourced as unregulated research-grade material.
Read Full recordStudied uses & evidence
Studied uses(6)
Neuroprotection against excitotoxic cell death in hippocampal neurons
LowProtected hippocampal and cortical neurons from excitotoxic damage in animal and cell studies only.
Improved neurological outcomes in traumatic brain injury models
LowImproved outcomes in animal brain-injury models. Human studies also examined prolonged disturbances of consciousness after head injury; these do not establish broad neuroprotective efficacy.
Protection of dopaminergic neurons in Parkinson's disease models (via taltirelin analog)
SpeculativePreliminary rodent studies suggest a TRH analog protects dopamine neurons, no human Parkinson's trials exist.
Evidence limits
- Evidence Level
- Moderate Evidence (diagnostic use approved; therapeutic analogs approved in Japan)
TRH (as protirelin) has decades of clinical use as a diagnostic agent for pituitary function testing. Its therapeutic neuroprotective potential has been demonstrated in clinical studies for TBI, depression, and spinal cord injury, but the very short half-life (~5 minutes) has limited its clinical development as a stand-alone drug. The TRH analog taltirelin (Ceredist) was approved in Japan in 2000 for spinocerebellar degeneration, validating the therapeutic concept. Several clinical trials have explored TRH in depression with positive preliminary results.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteLimited evidence: small pediatric epilepsy studies exist; they do not establish safety or efficacy for general pediatric use.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Transient TSH and thyroid hormone elevation
ModerateNausea, urge to urinate, flushing (with IV administration)
LowVery short half-life (~5 minutes) limiting therapeutic utility
LowBlood pressure changes
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.